Anti-idiotype antibodies can induce long-term complete remissions in non-Hodgkin's lymphoma without eradicating the malignant clone

The immunoglobulin on the surface of B-cell lymphomas can be a tumor-specific target for monoclonal antibody therapy. Between 1981 and 1993, 45 individuals with low grade B-cell lymphoma were treated with 52 courses of custom-made anti-idiotype antibodies. The antibodies were used either alone or in...

Full description

Saved in:

Bibliographic Details
Published in:	Blood Vol. 92; no. 4; p. 1184
Main Authors:	Davis, T A, Maloney, D G, Czerwinski, D K, Liles, T M, Levy, R
Format:	Journal Article
Language:	English
Published:	United States 15.08.1998
Subjects:	Animals Antibodies, Anti-Idiotypic - therapeutic use Antibodies, Monoclonal - therapeutic use Antibodies, Neoplasm - therapeutic use Antineoplastic Agents, Alkylating - therapeutic use B-Lymphocytes - pathology Biomarkers, Tumor - analysis Bone Marrow - pathology Chlorambucil - therapeutic use Chromosomes, Human, Pair 14 - ultrastructure Chromosomes, Human, Pair 18 - ultrastructure Clone Cells - pathology Combined Modality Therapy DNA, Neoplasm - analysis Enzyme-Linked Immunosorbent Assay Follow-Up Studies Humans Immunoglobulin Idiotypes - immunology Immunologic Factors - therapeutic use Interferon-alpha - therapeutic use Interleukin-2 - therapeutic use Lymphoma, B-Cell - drug therapy Lymphoma, B-Cell - pathology Lymphoma, B-Cell - therapy Lymphoma, Follicular - pathology Lymphoma, Follicular - therapy Mice Neoplasm Proteins - analysis Neoplasm Proteins - immunology Neoplasm, Residual Neoplastic Stem Cells - pathology Polymerase Chain Reaction Remission Induction Translocation, Genetic Treatment Outcome
ISSN:	0006-4971
Online Access:	Get more information
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!